Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHTEN-4: once-weekly eloralintide in adults with overweight or obesity and knee osteoarthritis pain
CTR20261932Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of eloralintide in obesity, Overweight, osteoarthritis (OA), sponsored by Eli Lilly and Company. Started Jun 2026; status: active.
02
Drugs
eloralintide
03
Conditions
obesityOverweightosteoarthritis (OA)
Beyond the preview
Go deeper on CTR20261932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261932.